Literature DB >> 23576497

APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells.

Julien Batisse1, Santiago Xavier Guerrero, Serena Bernacchi, Ludovic Richert, Julien Godet, Valérie Goldschmidt, Yves Mély, Roland Marquet, Hugues de Rocquigny, Jean-Christophe Paillart.   

Abstract

The HIV-1 viral infectivity factor (Vif) is a small basic protein essential for viral fitness and pathogenicity. Vif allows productive infection in nonpermissive cells, including most natural HIV-1 target cells, by counteracting the cellular cytosine deaminases APOBEC3G (apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G [A3G]) and A3F. Vif is also associated with the viral assembly complex and packaged into viral particles through interactions with the viral genomic RNA and the nucleocapsid domain of Pr55(Gag). Recently, we showed that oligomerization of Vif into high-molecular-mass complexes induces Vif folding and influences its binding to high-affinity RNA binding sites present in the HIV genomic RNA. To get further insight into the role of Vif multimerization in viral assembly and A3G repression, we used fluorescence lifetime imaging microscopy (FLIM)- and fluorescence resonance energy transfer (FRET)-based assays to investigate Vif-Vif interactions in living cells. By using two N-terminally tagged Vif proteins, we show that Vif-Vif interactions occur in living cells. This oligomerization is strongly reduced when the putative Vif multimerization domain ((161)PPLP(164)) is mutated, indicating that this domain is crucial, but that regions outside this motif also participate in Vif oligomerization. When coexpressed together with Pr55(Gag), Vif is largely relocated to the cell membrane, where Vif oligomerization also occurs. Interestingly, wild-type A3G strongly interferes with Vif multimerization, contrary to an A3G mutant that does not bind to Vif. These findings confirm that Vif oligomerization occurs in living cells partly through its C-terminal motif and suggest that A3G may target and perturb the Vif oligomerization state to limit its functions in the cell.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23576497      PMCID: PMC3648125          DOI: 10.1128/JVI.03494-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

1.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

2.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

3.  Monitoring of the formation and dissociation of polyethylenimine/DNA complexes by two photon fluorescence correlation spectroscopy.

Authors:  Jean Pierre Clamme; Joel Azoulay; Yves Mély
Journal:  Biophys J       Date:  2003-03       Impact factor: 4.033

4.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.

Authors:  Roberto Mariani; Darlene Chen; Bärbel Schröfelbauer; Francisco Navarro; Renate König; Brooke Bollman; Carsten Münk; Henrietta Nymark-McMahon; Nathaniel R Landau
Journal:  Cell       Date:  2003-07-11       Impact factor: 41.582

6.  Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression.

Authors:  Kim-Lien Nguyen; Manuel llano; Hirofumi Akari; Eri Miyagi; Eric M Poeschla; Klaus Strebel; Stephan Bour
Journal:  Virology       Date:  2004-02-20       Impact factor: 3.616

7.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.

Authors:  Hui Zhang; Bin Yang; Roger J Pomerantz; Chune Zhang; Shyamala C Arunachalam; Ling Gao
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

8.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

9.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.

Authors:  Mariana Marin; Kristine M Rose; Susan L Kozak; David Kabat
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

10.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Authors:  Kim Stopak; Carlos de Noronha; Wes Yonemoto; Warner C Greene
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

View more
  11 in total

1.  Core-binding factor subunit beta is not required for non-primate lentiviral Vif-mediated APOBEC3 degradation.

Authors:  Youwei Ai; Dantong Zhu; Cuihui Wang; Chao Su; Jian Ma; Jianzhang Ma; Xiaojun Wang
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

Review 2.  Structural insights for HIV-1 therapeutic strategies targeting Vif.

Authors:  Jason D Salter; Guillermo A Morales; Harold C Smith
Journal:  Trends Biochem Sci       Date:  2014-08-12       Impact factor: 13.807

3.  Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail.

Authors:  Dona Sleiman; Serena Bernacchi; Santiago Xavier Guerrero; Franck Brachet; Valéry Larue; Jean-Christophe Paillart; Carine Tisne
Journal:  RNA Biol       Date:  2014-07-22       Impact factor: 4.652

4.  An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.

Authors:  Ryan P Bennett; Ryan A Stewart; Priscilla A Hogan; Roger G Ptak; Marie K Mankowski; Tracy L Hartman; Robert W Buckheit; Beth A Snyder; Jason D Salter; Guillermo A Morales; Harold C Smith
Journal:  Antiviral Res       Date:  2016-11-05       Impact factor: 5.970

Review 5.  A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation.

Authors:  Ryan P Bennett; Jason D Salter; Harold C Smith
Journal:  Trends Mol Med       Date:  2018-03-30       Impact factor: 11.951

6.  The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation.

Authors:  María-Soledad Valera; Laura de Armas-Rillo; Jonathan Barroso-González; Serena Ziglio; Julien Batisse; Noé Dubois; Sara Marrero-Hernández; Sophie Borel; Laura García-Expósito; Martine Biard-Piechaczyk; Jean-Christophe Paillart; Agustín Valenzuela-Fernández
Journal:  Retrovirology       Date:  2015-06-24       Impact factor: 4.602

Review 7.  Monitoring Keap1-Nrf2 interactions in single live cells.

Authors:  Liam Baird; Sam Swift; David Llères; Albena T Dinkova-Kostova
Journal:  Biotechnol Adv       Date:  2014-03-25       Impact factor: 14.227

8.  Requirements for nucleocapsid-mediated regulation of reverse transcription during the late steps of HIV-1 assembly.

Authors:  Pierre-Jean Racine; Célia Chamontin; Hugues de Rocquigny; Serena Bernacchi; Jean-Christophe Paillart; Marylène Mougel
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

9.  A quick guide for using Microsoft OneNote as an electronic laboratory notebook.

Authors:  Santiago Guerrero; Andrés López-Cortés; Jennyfer M García-Cárdenas; Pablo Saa; Alberto Indacochea; Isaac Armendáriz-Castillo; Ana Karina Zambrano; Verónica Yumiceba; Andy Pérez-Villa; Patricia Guevara-Ramírez; Oswaldo Moscoso-Zea; Joel Paredes; Paola E Leone; César Paz-Y-Miño
Journal:  PLoS Comput Biol       Date:  2019-05-09       Impact factor: 4.475

10.  Clues for two-step virion infectivity factor regulation by core binding factor beta.

Authors:  Youwei Ai; Jianzhang Ma; Xiaojun Wang
Journal:  J Gen Virol       Date:  2017-05-18       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.